This ICR is
withdrawn, per NIH request. Should NIH resubmit this ICR, NIH shall
ensure that the changes in burden hours and costs are properly
reported in ROCIS (the burden hours and costs were not reported
correctly in this submission).
Inventory as of this Action
Requested
Previously Approved
11/30/2007
36 Months From Approved
02/29/2008
66,339
0
66,339
3,378
0
3,378
0
0
0
The NCI, as a sponsor of
investigational drug trials, has the responsibility to assure to
the FDA that systems for drug accountability are being maintained
by investigators in its clinical trials program. The data obtained
from the drug accountability record is used to track the dispensing
of investigational anticancer drugs from receipt from NIC to
dispensing or administration to patients. NCI and/or its auditors
for compliance reasons use this information.
The increase in burden from the
previous request is an adjustment. The increase in burden reflects
an increase in the number of IND's, protocols, investigators, and
drug shipments.
$500
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Mikia Currie 3014350941
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.